Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Publication | Closed Access

DOI

362

Citations

References

2017

Year

Joel E. Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S. Daar, David A. Wohl,

The Lancet

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyPharmacotherapyHiv-1 InfectionNon-inferiority TrialAntiviral DrugHivMedicinePhase 3